Notes Payable and Other Long-Term Liabilities | 7. Notes Payable and Other Long-term Liabilities Our debt obligations are as follows: Interest Rate September 30, December 31, (1) 2022 2021 (Unaudited) Monroe Term Loan (2) 9.06 % $ 61,228,651 $ 58,585,000 Green Remedies Promissory Note (3) 3.00 % 1,772,182 2,040,607 PNC ABL Facility (4) 4.56 % 11,904,062 7,234,737 Total notes payable 74,904,895 67,860,344 Less: Current portion of long-term debt ( 1,158,800 ) ( 1,329,109 ) Less: Unamortized debt issuance costs ( 2,238,842 ) ( 2,637,483 ) Less: Unamortized OID ( 314,356 ) ( 391,493 ) Less: Unamortized OID warrant ( 877,843 ) ( 1,093,058 ) Notes payable, net $ 70,315,054 $ 62,409,201 (1) Interest rates as of September 30, 2022 (2) Bears interest at LIBOR rate plus Applicable Margin ranging from 5.5 %- 7.5 % (3) Stated interest rate of 3.0 %, discounted cash flow rate of 13 % (4) Bears interest at a Base rate, as defined, plus a margin of 0.75 % to 1.25 % We capitalize financing costs we incur related to implementing our debt arrangements. We record these debt issuance costs associated with our revolving credit facility and our term loan as a reduction of long-term debt, net and amortize them over the contractual life of the related debt arrangements. The table below summarizes changes in debt issuance costs. September 30, 2022 (Unaudited) Debt issuance costs Beginning balance $ 2,637,483 Financing costs deferred 139,550 Less: Amortization expense ( 538,191 ) Debt issuance costs, net of accumulated amortization $ 2,238,842 Revolving Credit Facility On August 5, 2020, QRHC and certain of its domestic subsidiaries entered into a Loan, Security and Guaranty Agreement (the “PNC Loan Agreement”), which was subsequently amended on October 19, 2020 and December 7, 2021, with BBVA USA (which was subsequently succeeded in interest by PNC Bank, National Association (“PNC”)), as a lender, and as administrative agent, collateral agent, and issuing bank, which provides for a credit facility (the “ABL Facility”) comprising the following: • An asset-based revolving credit facility in the maximum principal amount of $ 15.0 million with a sublimit for issuance of letters of credit of up to 10 % of the maximum principal amount of the revolving credit facility. Each loan under the revolving credit facility bears interest, at the borrowers’ option, at either the Base Rate, plus a margin ranging from 0.75 % to 1.25 % ( 4.56 % as of September 30, 2022 ), or the LIBOR Lending Rate for the interest period in effect, plus a margin ranging from 1.75 % to 2.25 % ( no borrowings as of September 30, 2022 ). The maturity date of the revolving credit facility is April 19, 2025 . The revolving credit facility contains an accordion feature permitting the revolving credit facility to be increased by up to $ 10 million. • An equipment loan facility in the maximum principal amount of $ 2.0 million. Loans under the equipment loan facility may be requested at any time until August 5, 2023. Each loan under the equipment loan facility bears interest, at the borrowers’ option, at either the Base Rate, plus 1.75 %, or the LIBOR Lending Rate for the Interest Period in effect, plus 2.75 %. The maturity date of the equipment loan facility is April 19, 2025 . As of September 30, 2022 , the ABL Facility borrowing base availability was $ 15,000,000 , of which $ 11,904,062 principal was outstanding. It is possible that LIBOR may be phased out beginning in 2023. The ABL Facility provides procedures for determining a replacement or alternative rate in the event that LIBOR is unavailable. However, there can be no assurances as to whether such replacement or alternative rate will be more or less favorable than LIBOR. We intend to monitor the developments with respect to the potential phasing out of LIBOR beginning in 2023 and will work with PNC to ensure any transition away from LIBOR will have minimal impact on our financial condition. We, however, can provide no assurances regarding the impact of the discontinuation of LIBOR on the interest rate that we would be required to pay or on our financial condition. Monroe Term Loan On October 19, 2020, QRHC and certain of its domestic subsidiaries entered into a Credit Agreement (the “Credit Agreement”), dated as of October 19, 2020, which was subsequently amended on September 3, 2021, December 1, 2021, December 7, 2021, and August 9, 2022 with Monroe Capital, as administrative agent for the lenders thereto. Among other things, the Credit Agreement provides for the following: • A senior secured term loan facility in the outstanding principal amount of $ 61.2 million as of September 30, 2022. The senior secured term loan accrues interest at the LIBOR Rate for LIBOR Loans plus the Applicable Margin; provided, that if the provision of LIBOR Loans becomes unlawful or unavailable, then interest will be payable at a rate per annum equal to the Base Rate from time to time in effect plus the Applicable Margin for Base Rate Loans. The maturity date of the term loan facility is October 19, 2025 (the "Maturity Date"). The senior secured term loan will amortize in aggregate annual amounts equal to 1.00 % of the original principal amount of the senior secured term loan facility with the balance payable on the Maturity Date. Proceeds of the senior secured term loan are permitted to be used for Permitted Acquisitions (as defined in the Credit Agreement). • A delayed draw term loan facility in the maximum principal amount of $ 12.5 million. Loans under the delayed draw term loan facility may be requested at any time until March 31, 2023. Pricing and maturity for the outstanding principal amount of the delayed draw term loan shall be the same as for the senior secured term loan. Proceeds of the delayed draw term loan are to be used for Permitted Acquisitions. • An accordion term loan facility in the maximum principal amount of $ 5.3 million. Loans under the accordion loan facility may be requested at any time until the Maturity Date. Each accordion term loan shall be on the same terms as those applicable to the senior secured term loan. Proceeds of accordion term loans are permitted to be used for Permitted Acquisitions. The Credit Agreement contains certain financial covenants, including a minimum fixed charge coverage ratio and a senior net leverage ratio. In addition, the Credit Agreement contains negative covenants limiting, among other things, additional indebtedness, transactions with affiliates, additional liens, sales of assets, dividends, investments and advances, prepayments of debt, mergers and acquisitions, and other matters customarily restricted in such agreements. The Credit Agreement also contains customary events of default, including payment defaults, breaches of representations and warranties, covenant defaults, events of bankruptcy and insolvency, change of control, and failure of any guaranty or security document supporting the Credit Agreement to be in full force and effect. Upon the occurrence of an event of default, the outstanding obligations under the Credit Agreement may be accelerated and become immediately due and payable. At the same time as the borrowing of the initial $ 11.5 million under the Credit Agreement in October 2020, in a separate agreement, we issued Monroe Capital a warrant to purchase 500,000 shares of QRHC’s common stock exercisable immediately. For the delayed draw term loan facility, we issued a separate warrant to purchase 350,000 shares upon drawing on this facility on October 19, 2021. Both warrants have an exercise price of $ 1.50 per share and an expiration date of March 19, 2028 . We estimated the value of the warrants issued using the Black Scholes option pricing model and recorded a debt discount of approximately $ 766,000 in 2020 for the 500,000 -share warrant and $ 536,000 in 2021 for the 350,000 -share warrant which are being amortized over the term of the Credit Agreement. We also executed a letter agreement that provides that the warrant holder will receive minimum net proceeds of $ 1 million less any net proceeds received from the sale of the warrant shares, which is conditional on the full exercise and sale of all the warrant shares at the same time and upon a date two years after the closing date of such agreement. Green Remedies Promissory Note On October 19, 2020, we issued an unsecured subordinated promissory note to Green Remedies in the aggregate principal amount of $ 2,684,250 , payable commencing on January 1, 2021 in quarterly installments through October 1, 2025 and subject to an interest rate of 3.0 % per annum. Interest Expense The amount of interest expense related to borrowings for the three months ended September 30, 2022 and 2021 was $ 1,577,669 and $ 334,946 , respectively. The amount of interest expense related to borrowings for the nine months ended September 30, 2022 and 2021 was $ 4,097,400 and $ 1,030,377 , respectively. Debt issuance costs of $ 3,248,906 are being amortized to interest expense over the lives of the related debt arrangements. As of September 30, 2022 , the unamortized portion of the debt issuance costs was $ 2,238,842 . The amount of interest expense related to the amortization of debt issuance costs for the nine months ended September 30, 2022 and 2021 was $ 538,191 and $ 266,153 , respectively. Debt discount (“OID”) of $ 2,210,148 is being amortized to interest expense over the lives of the related debt and consideration arrangements. As of September 30, 2022 , the unamortized portion of OIDs was $ 1,192,199 . The amount of interest expense related to the amortization of OID costs for the nine months ended September 30, 2022 and 2021 is $ 440,196 and $ 349,418 , respectively. Other long-term liabilities September 30, December 31, 2022 2021 (Unaudited) Deferred consideration - earn-out $ 225,000 $ 781,000 Operating lease liability - long-term portion 1,850,542 1,123,799 Other 4,167 4,167 $ 2,079,709 $ 1,908,966 We recorded deferred consideration in connection with certain business acquisitions. We valued the earn-out liability using a Monte Carlo simulation. The inputs used in estimating the fair value of the earn-out liability represent Level 3 inputs under the fair value hierarchy. |